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ABSTRACT 
Background. Genital herpes simplex virus (HSV) infection causes recurrent lesions and 
frequent viral shedding. GEN-003 is a candidate therapeutic vaccine containing HSV-2 
gD2∆TMR and ICP4.2, and Matrix-M2 adjuvant. 
Methods. Persons with genital herpes were randomized into three dose cohorts to receive three 
intramuscular doses 21 days apart of 10 µg, 30 µg, or 100 µg of GEN-003, antigens without 
adjuvant, or placebo. Participants obtained genital area swabs twice-daily for HSV-2 detection 
and monitored genital lesions for 28-day periods at baseline and at intervals after the last dose. 
Results. One hundred and thirty-four persons received all three doses. Reactogenicity was 
associated with adjuvant, but not antigen dose or dose number. No serious adverse events were 
attributed to GEN-003. Compared to baseline, genital HSV-2 shedding rates immediately after 
dosing were reduced with GEN-003 (30 µg, from 13.4% to 6.4% [p<0.001]; 100 µg, from 15.0% 
to 10.3% [p<0.001]). Lesion rates were also significantly (p<0.01) reduced immediately 
following immunization with 30µg or 100µg GEN-003. GEN-003 elicited increases in antigen 
binding, virus neutralizing antibody, and T cell responses.  
Conclusions. GEN-003 had an acceptable safety profile and stimulated humoral and cellular 
immune responses. GEN-003, 30 µg and 100 µg, reduced genital HSV shedding and lesion 
rates. 
 
Clinical Trials Registration. www.ClinicalTrials.gov number: NCT01667341 (funded by 
Genocea). 
 
Keywords: genital herpes; herpes simplex virus type 2 infection; therapeutic vaccine; GEN-003; 
immunotherapy  
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BACKGROUND 
Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted infection that often results in 
recurrent genital lesions. Transmission occurs largely from asymptomatic genital tract virus shedding, 
making this a key target for a therapeutic HSV vaccine.  The management of genital herpes currently 
includes episodic or daily suppressive therapy with nucleoside analogues which abrogates most 
recurrences but only partly reduces viral shedding and transmission [1, 2]. 
GEN-003 contains a transmembrane deletion mutant of glycoprotein D (gD2∆TMR), a primary target 
antigen for neutralizing antibody and T cells, combined with a large fragment of infected cell protein 4 
(ICP4.2), an HSV-2 T cell antigen prioritized through human T cell screens.  This antigen was selected 
by comparing T cell responses of HSV-2-seropositive but asymptomatic and HSV-2-exposed seronegative 
individuals to individuals with recurrent disease using high-throughput HSV-2 proteomic screens [3].  
GEN-003, is a combination of these two proteins with a novel adjuvant, Matrix-M2 [4].  Preclinical studies 
have demonstrated that GEN-003 elicits antibody and T cell responses in mice and is protective in a guinea 
pig model of recurrent HSV-2 infection [5].   
We conducted a double-blind, placebo-controlled, dose-escalation Phase 1/2 study of GEN-003 to 
evaluate the safety, immunogenicity and effect on viral shedding of this candidate immunotherapy 
(ClinicalTrials.gov number, NCT01667341).  
 
METHODS 
Study Participants  
We recruited healthy, HSV-2 seropositive adults 18 to 50 years of age with a history of recurrent genital 
herpes for at least 1 year and 3 to 9 recurrences per year, in the absence of antiviral suppressive therapy.  
HSV-2 infection was documented by Western blot, HSV-2 HerpeSelect® 2 ELISA IgG (>3.5 index value), 
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HSV-2 IgG LIAISON® assay, or type-specific culture or PCR and confirmed for all subjects during 
screening by HSV-2 IgG LIAISON® assay.  Exclusion criteria included: immunocompromised state, 
antibody to HIV or Hepatitis C, presence of hepatitis B surface antigen, pregnant or nursing, history of 
genital HSV-1 infection, ocular HSV infection, HSV-related erythema multiforme, HSV meningitis or 
encephalitis, or prior receipt of HSV-2 vaccine.  Effective contraception was required throughout the 
study.  
 
Study Vaccine 
GEN-003 is a purified protein subunit vaccine consisting of a transmembrane deletion mutant of gD 
(gD2∆TMR) and a large fragment of infected cell protein 4 (ICP4.2) from HSV-2 (strain G) [5]. GEN-
003 also contained Matrix-M2 (Novavax, Gaithersburg, MD), 50 µg per dose.  Dulbecco’s phosphate 
buffered saline (DPBS), was used as diluent (or as placebo) to achieve a volume of 0.5 mL for 
intramuscular administration.  For the antigen only assigned subjects, Matrix-M2 was not added to the 
antigens. 
 
Study Procedures 
After obtaining informed consent but prior to randomization and dosing, participants obtained genital 
swab samples twice daily for 28 days and maintained a diary of genital lesions (baseline) [6]. To be eligible 
for randomization, subjects were required to provide a minimum of 44 baseline shedding swabs.  The 
swabbing procedure was repeated immediately after the third dose of vaccine and from weeks 29 to 33, 
and weeks 53 to 57 (referred to as 6 and 12 months after the last dose of vaccine, respectively).  The initial 
protocol specified only the first post-dosing shedding evaluation and was later amended to include 6 and 
12-month collection periods.  
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Participants were randomized into 3 cohorts sequentially, defined by antigen dose (10, 30, or 100 
µg of each antigen, Figure 1).  Within each dose cohort, participants were randomized at a 3:1:1 ratio to 
receive either complete GEN-003, HSV-2 antigens without the adjuvant (antigens only), or placebo.  
Subjects were randomized in blocks of 10 to assure an assignment to GEN-003, antigens only, and placebo 
at a ratio of 3:1:1 by a computer-based system.  The study product was administered intramuscularly in 
the deltoid approximately 21 days apart.  Study vaccine was prepared and administered by unblinded staff 
not involved in subsequent study procedures.  Investigators and other clinic personnel, as well as subjects 
were blinded to treatment assignment.  Clinical laboratory evaluation was performed prior to treatment 
and at intervals thereafter.  Blood was drawn for assessment of cellular immune response at baseline, 7 
days after each dose, and 6 and 12 months after the last dose.  Antibody responses to each antigen were 
evaluated on the day of each dose, and 6 and 12 months after the last dose. 
Subjects were followed for safety until 12 months after the last scheduled dose.  Adverse events 
(AEs) were captured from the first immunization until 28 days after the last dose. Solicited AEs including 
those generally associated with immunization were recorded by subjects for 7 days after each 
immunization.  Serious AEs (SAEs), and Adverse Events of Special Interest (AESI), consisting of a pre-
defined list of autoimmune disorders, were recorded through the end of the study. All AEs were graded 
by severity according to specified criteria 
(http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vacci
nes/ucm074775.htm). 
 
Study Oversight 
The study was designed collaboratively by investigators at Genocea Biosciences and University of 
Washington in accordance with the ethical principles of the Declaration of Helsinki and the principles of 
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current Good Clinical Practices. An independent Data and Safety Monitoring Board reviewed the 
cumulative data by dose cohort at specified intervals. The efficacy analyses reported were conducted by 
external statisticians and independently at the University of Washington, according to a previously 
developed statistical plan. Both academic and industry authors contributed to manuscript drafts and 
approved the submission of the final manuscript. The study authors had full access to all data, verified 
their accuracy, and vouch for the fidelity of the study to the protocol and the completeness of the data 
presented. The study was approved by the institutional review board at each study center and each 
participant provided written informed consent. 
 
Laboratory Methods 
HSV-2 DNA PCR. Genital swabs were tested for the presence of HSV-2 DNA using a quantitative real 
time polymerase chain reaction (PCR) method [5]. Each plate included four negative controls including 
two extraction and two PCR controls, and four 10-fold dilutions of HSV-2 strain 333 (positive controls).  
The limit of detection was 2 DNA copies per 20 µL reaction with linearity (R2 = 0.98) over 5 logs of HSV-
2 genomic DNA content.   
Antibody assays. IgG antibody responses directed against each of the GEN-003 antigens were 
measured by endpoint ELISA titer, as published previously [5].  HSV-2 neutralizing antibody titers were 
determined via a β-galactosidase (β-gal) colorimetric assay [5].   
Cellular immunity assays. Gamma interferon enzyme-linked immunospot assays (ELISPOTs) were 
performed as previously described with modifications for assays with human peripheral blood 
mononuclear cells [5]. 
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Statistical Methods 
The primary endpoint of the study was safety and tolerability, assessed by the frequency, nature, duration 
and severity of adverse events by the study group.  The secondary endpoints included the reduction in 
HSV shedding rate in participants following immunization, compared to baseline. Other secondary 
endpoints included the humoral and cellular immune responses to GEN-003 and the ability of Matrix-M2 
adjuvant to promote T cell responses.  Reduction in genital lesions was an exploratory endpoint.  
Efficacy and safety analyses were conducted on a modified intent-to-treat population that included 
all participants who received at least one dose of study vaccine. Because of the small number 
(approximately 10 each) assigned to the unadjuvanted dose and placebo groups within each dose cohort, 
results from these groups were reported as combined for all analyses except immune response analyses. 
Shedding rate was calculated as the number of positive swabs divided by the total number of swabs 
tested. An analysis of change from baseline in shedding rate (rate ratio) was performed using a previously 
described longitudinal Poisson mixed model with a random intercept to test for differences from baseline 
to each post-baseline time period within treatment group [6]. The model has the total positive swabs as 
the dependent variable and includes terms for treatment group, visit, treatment group by visit interaction, 
log of total swabs collected (offset) and a random intercept. With this model, the sample size of 30 subjects 
per treatment group was selected to detect a 30% reduction in the shedding rate of HSV-2 compared to 
baseline, with a power of 80% and a 2-sided α of 0.05, and assuming a 20% shedding rate at baseline.  
More recently, the statistical model was modified to include empirical variance estimate, as type I error 
was found to be greater than 5% using the previous method.  A recent study by Magaret comparing 
available methods for evaluating crossover studies for viral detection indicated that up to a 28% type I 
error was possible with previous methods but that type I error was controlled at 5% and power maximized 
using the empirical variance structure [7].  Since these simulation results were not available either at the 
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time of the writing of the statistical analysis plan or when the study data became available for analysis, 
we have included the primary analysis as well as updated analysis (see Supplementary Results and Table 
S1).  Because few subjects contributed data at 12 months, and the Poisson model failed to converge, this 
time-point was not included in the model and results are presented as descriptive only. 
Change from baseline to each of the follow-up visits was analyzed for antibody titers and T cell responses 
using a linear mixed model.  The model included terms for treatment group, baseline log titer, visit, 
treatment by visit interaction, and subject ID (random effect).  
 
RESULTS 
Study Population 
The trial was conducted at 7 sites in the United States between July 2012 and April 2014.  Of 204 persons 
screened, 143 (70%) were randomized and received at least one vaccination. The median age of 
participants was 37 (range 20–50); 62% were women (Table 1).  One hundred and thirty-four (94%) 
participants received all 3 doses of the study product (Figure 1) and 130 provided genital swabs during 
the 28 days immediately following the scheduled third immunization and were included in the efficacy 
analyses.  Some participants, including all participants in the 10 µg dose group, had completed the original 
protocol prior to an amendment to collect swab and blood samples 6 and 12 months after the last dose.  
Thus, 114 participants provided swabs at 6 months and 68 at 12 months following vaccination.  Overall, 
the percent of expected swabs collected was 96% (per-person median 98%, range 71 to 100). 
 
Safety and Tolerability of GEN-003 
Local and systemic reactions within the first hour after immunization were infrequent, and the most 
common were pain, tenderness, induration and redness at the injection site.  These were most frequent 
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among subjects receiving GEN-003, but all were graded as mild or moderate (data not shown).  In the first 
7 days following any of the 3 administered doses, 75% of placebo recipients, 100% of antigen only 
recipients, and 96 to 100% of GEN-003 recipients reported local reactogenicity at the site of administration 
(Figure 2; Table 2).  The most common reported systemic AEs for any of the 3 administered doses were 
myalgia and fatigue: 43% and 46% for placebo, 54% and 61% for antigen alone and 82% and 71% for 
GEN-003, respectively, without significant differences across antigen dose levels. Neither local nor 
systemic reactogenicity increased with subsequent doses of the vaccine (Figure 2), or with the dose of the 
antigen (Table 2). Grade 3 or 4 solicited AEs were experienced by 11% of placebo recipients, 7% of 
participants in the antigen only groups and in 42%, 21%, and 22% of participants in the 10, 30, and 100 
µg GEN-003 groups, respectively.  The most common Grade 3 and 4 local AEs were pain, tenderness and 
induration, and for systemic AEs were nausea, fatigue and myalgias (Table 2).  Participants who received 
GEN-003 had longer lasting adverse events, and reported using more analgesics following immunization 
than the participants in the antigen only or placebo groups. For example, pain was reported as a cumulative 
duration of 1.5 days (range: 1-2 days), 2 days (range: 1-7 days) and 3 days (range: 1-10 days) in the 
subjects receiving placebo, antigen only, and GEN-003, respectively. Three of 31 participants in the GEN-
003 10 µg dose group, but none in the other GEN-003 groups, discontinued dosing because of systemic 
reactogenicity.  Five unrelated SAEs were observed: femur fracture (GEN-003 10 µg, Day 185); suicide 
attempt (GEN-003 10 µg, Day 62); spontaneous miscarriage (placebo, Day 115); complex migraine 
(GEN-003 100 µg, Day 230) and myocardial infarction (GEN-003 100 µg, Day 370). No deaths or new 
onset immune-mediated diseases were noted.  
 
Immunogenicity of GEN-003 
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Immunization with GEN-003 elicited IgG and T cell responses to gD2∆TMR and ICP4.2 at all dose levels.  
IgG antibody responses were greatest with the 30 µg dose, while neutralizing antibody titers were the 
highest with the 100 µg dose.  For each antigen dose level, the addition of Matrix-M2 increased the 
responses (Figure 3).  T cell responses were highest for the lowest doses of GEN-003 (Figure 4). The IgG 
and T cell responses observed for both antigens in the GEN-003 groups after the third immunization were 
significantly higher than those in the same groups on Day 0 and those in the placebo group (p<0.001). A 
detailed description of immune responses to GEN-003, including the data collected at 6 and 12 months 
post immunization, has been published [8]. 
 
Effect of GEN-003 on Viral Shedding 
Among all subjects, HSV was detected in 11.9% (933 of 7824) of swabs collected at baseline, and ranged 
from 7.4% in the antigen only group to 15.0% in the GEN-003 100 µg dose group (Table 3).  In the 
placebo group, the rate ratio for viral shedding was unchanged immediately after immunization but 
appeared to increase at 6 months (RR=1.30, p=0.012).  In the antigen only group, the shedding rate 
increased from baseline (7.4%) to 10.0% immediately after immunization (RR=1.59, p=0.017), and was 
8.6% at 6 months (RR=2.22, p<0.001).   
The shedding rate for participants who received GEN-003 10 µg was unchanged immediately 
following the immunizations, but increased at 6 months (RR=1.58, p<0.001; Table 3).  Data at 12 months 
is not available for this dose group (see methods). In the GEN-003 30 µg group, the shedding rate was 
reduced 52% immediately following immunization (RR=0.47, p<0.001), and remained lower at 6 months 
(RR=0.58, p<0.001), returning close to baseline at 12 months.  Immunization with GEN-003 100 µg was 
also followed by a reduction in shedding immediately after immunizations (RR=0.68, p<0.001) that was 
not significant at 6 months (RR=0.88, p=0.224), and returned close to baseline at 12 months.  As observed 
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in similar studies of viral shedding, [9, 10] some subjects did not shed at baseline. This may explain the 
apparent increase in shedding after immunization among a few subjects (see Supplementary Figure S1). 
 
Effect of GEN-003 on Genital Lesions 
Lesion rates were similar before and after immunization for the placebo, antigen only and GEN-003 10 
µg groups (Table 3).  In the placebo group, a slight increase in the lesion rates at baseline was observed 
immediately after immunization where it remained at 6 months. Lesion rates then decreased at 12 months, 
but it should be noted that only a limited number of participants in the control group provided 12-month 
data (n=13). A similar pattern was observed in the antigen only group where lesion rates remained stable 
at 3 and 6 months but decreased at 12 months, possibly due to the smaller, more limited number of 
participants providing data (n=15).  The lesion rates were reduced for the GEN-003 30 µg group from 
9.7% to 5.0%, (RR=0.52, p<0.001), immediately after immunization and remained lower 6 and 12 months 
after immunizations (3.4% and 5.6%, respectively; RR=0.33, p<0.001 for the 6-month timepoint).  The 
lesion rates in the GEN-003 100 µg dose group were reduced immediately after immunization from 6.8% 
to 3.7% (RR=0.53, p=0.009), but not thereafter. 
As described in the methods, an alternative analysis of lesion and shedding rates using a Poisson 
regression method with empirical variance estimation can be found in Supplementary Table S1.  
 
DISCUSSION 
Our results of immunotherapy with GEN-003, a novel vaccine for genital herpes composed of HSV-2 
gD2∆TMR and a fragment of ICP4 protein (ICP4.2) adjuvanted with Matrix-M2, demonstrate that it had 
an acceptable safety profile, was immunogenic, and reduced both recurrent viral shedding and days with 
lesions at doses of 30 µg and 100 µg for each antigen.  Despite the frequent mild to moderate AEs 
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associated with injections, and the percentage of Grade 3 AEs, only 3 participants discontinued from 
further dosing. The addition of the Matrix-M2 adjuvant was critical for boosting the cell-mediated 
response and was dose-sparing for the antibody response to the vaccine.  
Most of the reactogenicity of GEN-003 was likely due to the addition of the adjuvant, Matrix-M2, 
to the viral antigens, and appeared acceptable for a therapeutic vaccine.  Reassuringly, no events of special 
interest emerged during the study.  While a few participants missed a day of work as a result of adverse 
events, study discontinuation caused by these events was rare, further indicating that the safety profile, as 
observed in this trial, was acceptable to participants.  
Prior attempts to develop a therapeutic vaccine for HSV-2 were unsuccessful.  Some of the prior 
candidate vaccines focused on eliciting IgG and neutralizing antibody responses to surface antigens [11]. 
It had been hypothesized that effective T cell responses are likely to be required to control intracellular 
pathogens such as HSV. However, in this study the level of T cells, at least as measured by gamma 
interferon ELISPOT did not correlate to the clinical reductions; the frequencies of responding T cells were 
highest in the 10 µg group which had little to no impact on viral shedding or lesion rates.  Additionally, a 
replication defective (gH deletion) mutant virus failed in a double-blind, randomized study to reduce 
recurrence rates or viral shedding in subjects with genital HSV-2 although T cell immune responses were 
identified in animals [12, 13]. The specific T cell target may be critical to eliciting an effective immune 
response.  We previously identified ICP4 as a potential T cell target from HSV-2 using a high throughput 
antigen-screening methodology [3]. 
GEN-003 elicited both humoral and cellular immune responses.  Antibody titers directed against 
gD2∆TMR and ICP4.2 increased after each dose [8] and  peaked at 30 µg. Titers of neutralizing antibody 
were the highest in subjects who received the 100 µg dose.  By contrast, T cell responses, measured by 
gamma interferon ELISPOT were maximal after the first dose, and appeared to be inversely related to 
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antigen dose [8].  A similar effect was identified in pre-clinical studies of immunogenicity in mice [5].  
Chronic infections may induce high or chronic loads of antigen, and after vaccination, T cells may become 
anergised, exhausted or die of apoptosis [14]. Additional analyses are underway to explore the correlate 
of activity.   
Viral shedding was used as the main efficacy outcome because it is an objective measure of 
mucosal HSV replication, its measurement has been previously used to demonstrate differences in efficacy 
between doses of antiviral therapies [6], and it is the primary mode for transmission [15].  Consequently, 
for dose selection of a therapeutic agent, shedding rates are most efficient and quantitative, keeping in 
mind that shedding was measured by QPCR and thus infectious virus was not measured directly.  There 
are inherent limitations of comparing results from across trials due to differences in study design, patient 
populations, exclusion/inclusion criteria and endpoints measured. In the current study, the 6.4% of positive 
swabs detected in the 30 µg group after the last dose is similar to that observed in a study with valacyclovir 
(500 mg daily) of 4–6% [6].  
Immunization with GEN-003 at 30 and 100 µg significantly reduced viral shedding and clinical 
disease (lesion rate) immediately after vaccination. At 6 months after immunization, significant reductions 
in viral shedding and lesion rates continued to be observed in the 30 µg group while only a reduction in 
lesion rate was observed in the 100 µg dose group.  However, no such conclusion can be stated for the 
results at 12 months due to the limited number of subjects who provided data at this time.  Changes 
between 6- and 12-month measurements may simply reflect this reduction in number of subjects, and 
further studies are required to assess the durability of response.  Furthermore, although shedding is most 
certainly a requirement for transmission, no quantitative data exists to allow extrapolation from the 
observed reduction in shedding to a possible benefit on transmission.  The durability of response is 
encouraging although the number of participants in the study at the 12-month evaluation period was small 
15 
 
and may explain the apparent fall in lesion rates observed in the control groups.  Currently, the data 
indicate a durability of 6 months, an interval likely to be practical to implement for maintenance dosing 
of a therapeutic vaccine. Further studies are being conducted to better estimate true durability of effect. 
The importance of an effective HSV-2 vaccine has been reviewed recently in an article prepared for the 
WHO Product Development for Vaccines Advisory Committee (PDVAC) [16]. HSV and the 
complications associated with infections are such that an effective HSV vaccine will have significant 
clinical and economic impacts. 
In conclusion, GEN-003, a novel therapeutic vaccine for HSV-2 currently in clinical development, 
was shown to have an acceptable safety profile, reduce viral shedding, reduce the frequency of genital 
lesions and boost the humoral and cellular immune responses to HSV-2.  The optimal dose of the proteins 
and adjuvant, and the durability of the effect will require further study. 
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Table 1. Demographic and Clinical Characteristics of Study Participants, by Study Arm 
Characteristic Placebo 
N=28 
 Antigen 
only 
N=28 
GEN–003, 
10 µg 
N=31 
GEN–003, 
30 µg 
N=29 
GEN–003, 
100 µg 
N=27 
Median age, year (range) 36.5 (23–50) 37 (20–47) 37 (24–49) 38 (22–50) 34 (24–50) 
Female sex, n (%) 17 (61) 17 (61) 21 (68) 18 (62) 15 (56) 
Caucasian, n (%) 17 (61) 15 (54) 23 (74) 16 (55) 17 (63) 
African American, (%) 10 (36) 8 (29) 5 (16) 10 (35) 8 (30) 
HSV-1+/2+, n (%) 11/25 (44) 16/25 (64) 15/26 (56) 5/22 (22) 14/25 (56) 
Median duration of genital 
herpes, years (range) 
6.5 (1–26) 6.0 (0–24)a 6.0 (1–33) 8.0 (1–25) 6.0 (2–33) 
Frequency of recurrences 
prior to study entry, b  
median per year (range) 
5 (3–8) 5 (3–9) 5 (3–8) 5 (3–9) 5 (3–9) 
Ever on suppressive therapy 
prior to study entry, n (%) 
21 (75) 19 (68) 18 (58) 18 (62) 11 (41) 
Swabs prior to immunization, 
total n (per person median, 
range) 
1527 
(55, 50–56) 
1531 
(56, 51–56) 
1707 
(56, 50–56) 
1576 
(56, 49–56) 
1483 
(56, 50–56) 
Swabs post immunization,  
total n (per person median, 
range) 
1373 
(56, 37–56) 
1365 
(56, 31–56) 
1361 
(55, 13–56) 
1414 
(54, 26–56) 
1346 
(55, 27–56) 
Swabs at 6 months,  
total n (per person median, 
range) 
1287 
(56, 45–69) 
1183 
(55, 41–64) 
1414 
(56, 40–68) 
1017 
(55, 46–57) 
1323 
(56, 36–69) 
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Swabs at 12 months,  
n (per person median, range) 
730 
(56, 50–62) 
834 
(56, 49–60) 
– 1080 
(56, 33–59) 
1108 
(56, 51–58) 
aOne subject had a formal diagnosis of genital HSV-2 infection only 6 months before randomization rather than 1 
year as required by the inclusion criteria but had been symptomatic for much longer. Enrollment of this subject 
was approved by the Sponsor 
bDuring year prior to initiation of suppressive therapy for those on suppressive therapy 
Abbreviations: HSV, Herpes simplex virus; n, number 
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Table 2: Adverse Events Reported Following any Dose of Administered Study Treatmenta 
Event, n (%) Placebo 
N=28 
Antigen 
only 
N=28 
GEN-003, 
10 µg 
N=31 
GEN-003, 
30 µg 
N=29 
GEN-003, 
100 µg 
N=27 
Total solicited adverse 
events 
21 (75) 28 (100) 31 (100) 28 (97) 26 (96) 
Grade 3 or 4 solicited 
adverse events, total 
3 (11) 2 (7) 13 (42) 6 (21) 6 (22) 
Injection-site reactions, 
Grade 3 or 4 
     
    Pain 0 0 5 (16) 0 3 (11) 
    Tenderness 0 1 (4) 5 (16) 3 (10) 3 (11) 
    Induration 0 0 1 (3) 2 (7) 3 (11) 
    Redness 0 0 1 (3) 1 (3) 0 
Systemic reactions, 
Grade 3 or 4 
     
    Nausea 1 (4) 0 6 (19) 2 (7) 1 (4) 
    Vomiting 0 0 3 (10) 1 (3) 0 
    Diarrhea 0 0 0 0 0 
    Fatigue 3 (11) 2 (7) 7 (23) 2 (7) 4 (15) 
    Myalgia 1 (4) 0 8 (26) 3 (10) 4 (15) 
    Fever 0 0 3 (10) 0 1 (4) 
Other adverse events 
     
    Any adverse event 20 (71) 21 (75) 27 (87) 18 (62) 16 (59) 
    Grade 3 or 4 3 (11) 1 (4) 7 (23) 3 (11) 3 (11) 
22 
 
    Serious adverse event 1 (4) 0 (0) 2 (6) 0 (0) 2 (7) 
   Adverse event leading 
to discontinuation 
0 (0) 0 (0) 3 (10) 0 (0) 0 (0) 
aAll AEs were graded by severity according to specified criteria 
(http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccin
es/ucm074775.htm)  
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Table 3. Genital HSV-2 Shedding and Lesions Rates Before and After Immunization 
Characteristic Placebo 
N=28 
Antigen 
only 
N=28 
GEN-003,  
10 µg 
N=31 
GEN-003,  
30 µg 
N=29 
GEN-003, 
100 µg 
N=27 
HSV shedding rate per swab, n/n (%) 
 Pre-vaccine 190/1527 
(12.4) 
114/1531 
(7.4) 
185/1707 
(10.8) 
221/1576 
(13.4) 
223/1483 
(15.0) 
 First period post 
immunization 
176/1373 
(12.8) 
136/1365  
(10.0) 
147/1361  
(10.8) 
91/1414  
(6.4) 
138/1346 
(10.3) 
 At 6 months 214/1287  
(16.6) 
102/1183  
(8.6) 
244/1414  
(17.3) 
81/1017  
(8.0) 
164/1323  
(12.4) 
 At 12 months 90/730 
(12.3) 
120/834 
(14.4) 
NA 133/1080 
(12.3) 
123/1108 
(11.1) 
Rate ratio for HSV shedding relative to pre-immunizationa 
 First period post 
immunization 
0.95 1.59b 1.06 0.47c 0.68c 
 At 6 months 1.30b 2.22c 1.58c 0.58c 0.88 
Lesion rate, n/n (%) 
 Pre-vaccine 59/820 
(7.2) 
76/804 
(9.5) 
128/873 
(14.7) 
79/816 
(9.7) 
52/761 
(6.8) 
 First period post 
immunization 
67/737  
(9.1) 
48/721 
(6.7) 
64/711  
(9.0) 
38/760  
(5.0) 
26/708 
(3.7) 
 At 6 months 61/665 
(9.2) 
41/611 
(6.7) 
82/733 
(11.2) 
18/532 
(3.4) 
32/691 
(4.6) 
 At 12 months 15/372 11/427 NA 31/556 33/569 
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(4.0) (2.6) (5.6) (5.8) 
Rate ratio for lesions relative to pre-immunizationa 
 First period post 
immunization 
1.21 0.90 0.76 0.52d 0.53d 
 At 6 months 1.32 1.23 0.91 0.33c 0.85 
aA limited number of participants collected swabs and reported lesions in the Weeks 53 to 57 period, so the Poisson 
mixed model failed to converge for this period, thus, 12-month comparisons are not presented. 
bp<0.05; cp<0.001; dp<0.01. An analysis of change from baseline in shedding rate was performed using a previously 
described longitudinal Poisson mixed model with a random intercept to test for differences from baseline to each 
post-baseline time period within treatment group [6]. The model has the total positive swabs as the dependent 
variable and includes terms for treatment group, visit, treatment group by visit interaction, log of total swabs 
collected (offset) and a random intercept. 
Abbreviations: HSV, Herpes simplex virus. 
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Figure Legends 
Figure 1.  Consort diagram of the study. 
 
Figure 2. Rates of local and systemic solicited adverse events within 7 days following 
vaccination by treatment assignment and dose number  
 
Figure 3.  Humoral immune responses following the third immunization measured on Day 63, 3 
weeks post the third immunization. Values represent the geometric mean titer (GMT) with 95% 
confidence intervals (CI). A. IgG response to glycoprotein gD2∆TMR; B. IgG response to 
ICP4.2; C. NAb response 
* p<0.001 compared with placebo and compared with Day 0 in the same group   
Abbreviations: CI, confidence interval; gD2∆TMR, a transmembrane deletion mutant of 
glycoprotein D; GMT, geometric mean titer; ICP4.2, infected cell protein 4; Nab, neutralizing 
antibody. 
 
Figure 4.  Cellular immune responses measured on Day 49, 1 week post the third immunization. 
The mean spot-forming units (SFU)/106 cells with 95% CI are shown.  A. Interferon-γ release to 
glycoprotein D2; B. Interferon-γ release to ICP4.2 
* p<0.001 compared with placebo and compared with Day 0 in the same group 
Abbreviations: CI, confidence interval; gD2, glycoprotein D2; ICP4.2, infected cell protein 4; 
IFN-γ, interferon-γ; SFU, spot-forming units. 
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Figure 1 
 
 
Abbreviations: CI, confidence interval; gD2, glycoprotein D2; ICP4.2, infected cell protein 4; 
IFN-γ, interferon-γ; SFU, spot-forming units. 
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Figure 2
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Figure 3
 
* p<0.001 compared with placebo and compared with Day 0 in the same group    
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Figure 4 
 
* p<0.001 compared with placebo and compared with Day 0 in the same group   
